Cancer and therapeutic vaccines at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
15 organizations at World Vaccine Congress Europe 2026 present work in cancer & therapeutic vaccines: 5 vaccine and drug developers, 5 suppliers and service providers, 3 public-health and non-profit bodies and 2 academic bodies. Between them they bring 40 presentations to the program. Most represented: Sanofi (8 on the program), University of Oxford (6 on the program), European Medicines Agency (4 on the program). 12 of them have their own page in this guide. As of Sep 26, 2026.
All 251 organizations at World Vaccine Congress Europe 2026 →
Format
Top represented
Showing 1–10 of 15 organizations
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
Sanofi Paris, France | |
Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs. | Talk Mon Oct 19 11:30 Talk Mon Oct 19 14:45 Talk Mon Oct 19 15:30 Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Talk Wed Oct 21 13:30 Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
University of Oxford Oxford, UK | |
Talk Mon Oct 19 10:00 Talk Mon Oct 19 11:45 Talk Tue Oct 20 16:30 Talk Wed Oct 21 10:30 Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. | |
European Medicines Agency Amsterdam, Netherlands | |
The European Union's medicines regulator, evaluating and monitoring vaccines and medicines. | Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. Panel Mon Oct 19 14:15 Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up. Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. Supply, safety & access Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
BioNTech Mainz, Germany | |
Develops mRNA vaccines and immunotherapies for infectious diseases and cancer, including the marketed COVID-19 vaccine Comirnaty. | Talk Mon Oct 19 10:15 Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Wed Oct 21 12:30 |
Uses its AI-Immunology platform to discover and design vaccines against bacterial and viral infections and cancer. | Booth Exhibiting at Booth 216 Talk Wed Oct 21 11:00 Talk Wed Oct 21 11:30 |
Develops silicon microneedle devices for intradermal delivery; its lead product, Bella-mu, administers volumes up to 0.5 mL. | Booth Exhibiting at Booth 540 Talk Wed Oct 21 10:30 How can a microneedle manufacturer contribute to the success of cancer vaccine developers? Cancer & therapeutic vaccinesPlatforms & delivery |
SB Sagitta Biotech | |
Develops targeted viral vectors that deliver toxic payloads to solid tumors, with efficacy data in glioblastoma. | Talk Wed Oct 21 10:40 |
Frederick National Laboratory for Cancer Research Frederick, MD | |
Talk Mon Oct 19 10:30 Talk Tue Oct 20 14:00 Talk Tue Oct 20 16:00 | |
Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. Talk Tue Oct 20 14:00 | |
National Cancer Institute Bethesda, MD | |
Talk Mon Oct 19 10:00 Talk Mon Oct 19 10:00 |
Instantly find 20 buyers in cancer & therapeutic vaccines
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World Vaccine Congress Europe 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction